\u4efb\u547dProfessor Michael Wall\u4e3a\u8bd5\u9a8c\u6307\u5bfc\u5c0f\u7ec4\u4e3b\u5e2d\u3002<\/a>Wall\u6559\u6388\u88ab\u8ba4\u4e3a\u662fIIH\u9886\u57df\u7684\u6770\u51fa\u4e13\u5bb6\uff0c\u4ed6\u53d1\u8868\u4e86\u5e7f\u6cdb\u7684\u8bba\u6587\uff0c\u5728\u795e\u7ecf\u75c5\u5b66\u548c\u773c\u79d1\u7684\u4e34\u5e8a\u8bd5\u9a8c\u6267\u884c\u65b9\u9762\u6709\u4e30\u5bcc\u7684\u7ecf\u9a8c\u548c\u4e13\u4e1a\u77e5\u8bc6\u3002<\/p>\n\u9000\u7a0e<\/h2>\n
\u540c\u6837\u5728\u672c\u5b63\u5ea6\uff0cInvex\u82f1\u56fd\u5b50\u516c\u53f8\u4ece\u82f1\u56fd\u653f\u5e9c\u83b7\u5f97\u4e86\u7ea610\u4e07\u82f1\u9551(\u540818.4\u4e07\u6fb3\u5143)\u76842021\u8d22\u5e74\u7814\u53d1\u9000\u7a0e\u3002<\/p>\n
\u8be5\u516c\u53f8\u8868\u793a\uff0c\u968f\u7740\u516c\u53f8\u63d0\u524d\u652f\u51fa\u4ee5\u652f\u6301\u5176\u6ce8\u518c\u5bfc\u5411\u7684IIH\u6f14\u8fdb\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\uff0c\u9884\u8ba1\u672a\u6765\u4e00\u6bb5\u65f6\u95f4\u5185\uff0c\u82f1\u56fd\u9000\u7a0e\u5c06\u589e\u52a0\uff0c\u6fb3\u5927\u5229\u4e9a\u7814\u53d1\u9000\u7a0e\u4e5f\u5c06\u5f00\u59cb\u3002<\/p>\n
\u4e0ePeptron\u7684\u521d\u6b65\u91c7\u8d2d\u8ba2\u5355<\/h2>\n
\u57289\u6708\u7684\u5b63\u5ea6\u4e2d\uff0cInvex\u4e0ePeptron\u8fbe\u6210\u4e86\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\u3002Invex\u62a5\u544a\u79f0\uff0c\u5bf9Peptron\u5728\u97e9\u56fd\u7684\u5236\u9020\u5de5\u5382\u548c\u53e6\u4e00\u5bb6\u5173\u952e\u4f9b\u5e94\u5546\u8fdb\u884c\u4e86\u4ee4\u4eba\u6ee1\u610f\u7684\u72ec\u7acb\u5408\u683c\u4eba\u5458\u5ba1\u8ba1\uff0c\u8be5\u5de5\u5382\u6bcf\u6708\u53ef\u751f\u4ea748,000\u74f6Presendin\u3002<\/p>\n
\u6839\u636e\u6b27\u76df\u548c\u82f1\u56fd\u6cd5\u5f8b\uff0c\u8fd9\u79cd\u4ee4\u4eba\u6ee1\u610f\u7684\u5ba1\u6838\u548c\u968f\u540e\u7531\u6709\u8d44\u683c\u7684\u4eba\u5bf9\u836f\u54c1\u751f\u4ea7\u6279\u6b21\u7684\u8ba4\u8bc1\u662f\u5728\u5c06\u4ea7\u54c1\u8fdb\u53e3\u5230\u8be5\u5730\u533a\u7528\u4e8e\u4e34\u5e8a\u6216\u5546\u4e1a\u76ee\u7684\u4e4b\u524d\u7684\u8981\u6c42\u3002<\/p>\n
\u6b64\u6b21\u5ba1\u6838\u6210\u529f\u540e\uff0cInvex\u5df2\u4e0ePeptron\u7b7e\u8ba2\u4e86\u4e00\u4efd\u521d\u6b65\u91c7\u8d2d\u8ba2\u5355\uff0c\u4e3aIIH ELVOLVE\u8bd5\u9a8c\u63d0\u4f9bPresendin\u548c\u5b89\u6170\u5242\u7684\u4e34\u5e8a\u6279\u6b21\u3002Invex\u7684\u4ed3\u50a8\u548c\u5206\u9500\u5408\u4f5c\u4f19\u4f34\u9884\u8ba1\u5c06\u5728\u77ed\u671f\u5185\u53d1\u8d27\uff0c\u5e76\u5b8c\u6210\u5fc5\u8981\u7684\u6807\u7b7e\u8981\u6c42\uff0c\u4ee5\u4fbf\u5728\u8bca\u6240\u5f00\u4e1a\u540e\u7acb\u5373\u53d1\u8d27\u3002<\/p>\n
\u8bd5\u9a8c\u8d44\u91d1\u5145\u8db3<\/h2>\n
\u622a\u81f3\u53bb\u5e7412\u6708\u5f53\u5b63\u672b\uff0cInvex\u7684\u73b0\u91d1\u548c\u73b0\u91d1\u7b49\u4ef7\u7269\u4e3a3,140\u4e07\u7f8e\u5143\u3002<\/p>\n
\u672c\u5b63\u5ea6\u7684\u73b0\u91d1\u6d41\u51fa\u603b\u989d\u4e3a60\u4e07\u7f8e\u5143\uff0c\u5305\u62ec\u4e0epreendin\u548c\u5b89\u6170\u5242\u8d2d\u4e70\u76f8\u5173\u7684\u4ea7\u54c1\u5236\u9020\u548c\u8fd0\u8425\u6210\u672c\uff0c\u4ee5\u51c6\u5907IIH EVOLVE\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\uff0c\u7814\u7a76\u548c\u5f00\u53d1\u652f\u51fa\u4ee5\u53ca\u7ba1\u7406\u548c\u4f01\u4e1a\u6210\u672c\u3002<\/p>\n
\u8be5\u516c\u53f8\u8868\u793a\uff0c\u5df2\u4ece\u5f53\u524d\u73b0\u91d1\u50a8\u5907\u4e2d\u83b7\u5f97\u8db3\u591f\u8d44\u91d1\u6765\u5b8c\u6210IIH\u6f14\u8fdb\u7b2c\u4e09\u9636\u6bb5\u7684\u8bd5\u9a8c\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"
\u65e5\u524d\uff0cInvex Therapeutics (ASX: IXC)\u5728\u5176IIH EVOLVE 3\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u51c6\u5907\u5de5\u4f5c\u4e0a\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u5b9e\u73b0\u836f\u7269Presendin\u7528\u4e8e\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684\u5168\u7403\u6ce8\u518c\u3002 \u5728\u4eca\u5929\u53d1\u5e03\u7684\u5b63\u5ea6\u66f4\u65b0\u4e2d\uff0c\u8fd9\u5bb6\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u8868\u793a\uff0c\u5b83\u5df2\u5411\u7279\u5b9a\u7684\u4eba\u7c7b\u7814\u7a76\u4f26\u7406\u59d4\u5458\u4f1a(HREC)\u63d0\u4ea4\u4e86\u9996\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\uff0c\u8ba1\u5212\u4e8e12\u6708\u5728\u6fb3\u5927\u5229\u4e9a\u5f00\u59cb\u8bd5\u9a8c\u3002 \u5728\u6fb3\u5927\u5229\u4e9a\uff0c\u6839\u636e\u300a\u6cbb\u7597\u7528\u54c1\u6cd5\u300b\uff0cHRECs\u88ab\u8981\u6c42\u5ba1\u67e5\u548c\u76d1\u6d4b\u6240\u6709\u672a\u6ce8\u518c\u836f\u7269\u7684\u4e34\u5e8a\u8bd5\u9a8c\u3002\u5982\u679c\u6210\u529f\uff0cHREC\u6e05\u9664\u5c06\u5141\u8bb8Invex\u5728\u6279\u51c6\u7684\u8bd5\u9a8c\u65b9\u6848\u53c2\u6570\u4e0b\u5f00\u59cb\u62db\u52dfIIH\u60a3\u8005\u3002 Invex\u8868\u793a\uff0c\u8ba1\u5212\u5728\u6fb3\u5927\u5229\u4e9a\u8bbe\u7acb\u201c\u591a\u4e2a\u201d\u4e34\u5e8a\u8bd5\u9a8c\u5730\u70b9\uff0c\u5e76\u9884\u8ba1\u57282022\u5e74\u4e0a\u534a\u5e74\u5b8c\u6210\u82f1\u56fd\u3001\u6b27\u6d32\u548c\u7f8e\u56fd\u7684\u66f4\u591a\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u3002 \u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u51c6\u5907 \u7ecf\u8fc7\u91cd\u8981\u7684\u79d1\u5b66\u548c\u76d1\u7ba1\u54a8\u8be2\uff0cInvex\u572812\u6708\u7684\u5b63\u5ea6\u5b8c\u6210\u4e86\u5176\u603b\u4f53\u76d1\u7ba1\u548c\u4e34\u5e8a\u8bd5\u9a8c\u6218\u7565\u3002 \u8ba1\u5212\u4e2d\u7684\u5355\u671f\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u65e8\u5728\u6ee1\u8db3Presendin\u7528\u4e8eIIH\u6cbb\u7597\u5728\u6b27\u76df\u3001\u82f1\u56fd\u548c\u6fb3\u5927\u5229\u4e9a\u7684\u5e02\u573a\u6279\u51c6\u8981\u6c42\u3002 \u8be5\u8bd5\u9a8c\u8ba1\u5212\u62db\u52df240\u540d\u65b0\u8bca\u65ad\u7684IIH\u60a3\u8005\uff0c\u8fd9\u4e9b\u60a3\u8005\u5c06\u968f\u673a\u63a5\u53d7\u6bcf\u5468\u4e00\u6b21\u7684Presendin\u76ae\u4e0b\u6ce8\u5c04\u6216\u5b89\u6170\u5242\uff0c\u8fd9\u4e9b\u836f\u7269\u5206\u5e03\u5728\u6b27\u6d32\u3001\u82f1\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u548c\u7f8e\u56fd\u768437\u4e2a\u8bd5\u9a8c\u4e2d\u5fc3\u3002 \u8be5\u8bd5\u9a8c\u7684\u4e3b\u8981\u7ec8\u70b9\u5c06\u8bc4\u4f30\u63a5\u53d7Presendin\u548c\u5b89\u6170\u5242\u7684\u60a3\u8005\u572824\u5468\u65f6\u9885\u5185\u538b\u529b\u4e0e\u57fa\u7ebf\u7684\u5e73\u5747\u5dee\u5f02\u3002 \u6b21\u8981\u7ec8\u70b9\u5c06\u8bc4\u4f30\u4e24\u7ec4\u572824\u5468\u5185\u89c6\u529b\u548c\u6bcf\u6708\u5934\u75db\u5929\u6570\u7684\u76f8\u5bf9\u5dee\u5f02\u3002 \u8be5\u8bd5\u9a8c\u7684\u7ed3\u679c\u6709\u671b\u4fc3\u8fdb\u672a\u6765\u4e0e\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40(FDA)\u5c31Presendin\u5728\u7f8e\u56fd\u6ce8\u518c\u8fdb\u884c\u8ba8\u8bba\u3002 \u8bd5\u9a8c\u7b79\u5907\u5de5\u4f5c\u7684\u4e00\u4e2a\u91cc\u7a0b\u7891\u662f\u4efb\u547dProfessor Michael Wall\u4e3a\u8bd5\u9a8c\u6307\u5bfc\u5c0f\u7ec4\u4e3b\u5e2d\u3002Wall\u6559\u6388\u88ab\u8ba4\u4e3a\u662fIIH\u9886\u57df\u7684\u6770\u51fa\u4e13\u5bb6\uff0c\u4ed6\u53d1\u8868\u4e86\u5e7f\u6cdb\u7684\u8bba\u6587\uff0c\u5728\u795e\u7ecf\u75c5\u5b66\u548c\u773c\u79d1\u7684\u4e34\u5e8a\u8bd5\u9a8c\u6267\u884c\u65b9\u9762\u6709\u4e30\u5bcc\u7684\u7ecf\u9a8c\u548c\u4e13\u4e1a\u77e5\u8bc6\u3002 \u9000\u7a0e \u540c\u6837\u5728\u672c\u5b63\u5ea6\uff0cInvex\u82f1\u56fd\u5b50\u516c\u53f8\u4ece\u82f1\u56fd\u653f\u5e9c\u83b7\u5f97\u4e86\u7ea610\u4e07\u82f1\u9551(\u540818.4\u4e07\u6fb3\u5143)\u76842021\u8d22\u5e74\u7814\u53d1\u9000\u7a0e\u3002 \u8be5\u516c\u53f8\u8868\u793a\uff0c\u968f\u7740\u516c\u53f8\u63d0\u524d\u652f\u51fa\u4ee5\u652f\u6301\u5176\u6ce8\u518c\u5bfc\u5411\u7684IIH\u6f14\u8fdb\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\uff0c\u9884\u8ba1\u672a\u6765\u4e00\u6bb5\u65f6\u95f4\u5185\uff0c\u82f1\u56fd\u9000\u7a0e\u5c06\u589e\u52a0\uff0c\u6fb3\u5927\u5229\u4e9a\u7814\u53d1\u9000\u7a0e\u4e5f\u5c06\u5f00\u59cb\u3002 \u4e0ePeptron\u7684\u521d\u6b65\u91c7\u8d2d\u8ba2\u5355 \u57289\u6708\u7684\u5b63\u5ea6\u4e2d\uff0cInvex\u4e0ePeptron\u8fbe\u6210\u4e86\u957f\u671f\u5408\u4f5c\u548c\u751f\u4ea7\u534f\u8bae\u3002Invex\u62a5\u544a\u79f0\uff0c\u5bf9Peptron\u5728\u97e9\u56fd\u7684\u5236\u9020\u5de5\u5382\u548c\u53e6\u4e00\u5bb6\u5173\u952e\u4f9b\u5e94\u5546\u8fdb\u884c\u4e86\u4ee4\u4eba\u6ee1\u610f\u7684\u72ec\u7acb\u5408\u683c\u4eba\u5458\u5ba1\u8ba1\uff0c\u8be5\u5de5\u5382\u6bcf\u6708\u53ef\u751f\u4ea748,000\u74f6Presendin\u3002 \u6839\u636e\u6b27\u76df\u548c\u82f1\u56fd\u6cd5\u5f8b\uff0c\u8fd9\u79cd\u4ee4\u4eba\u6ee1\u610f\u7684\u5ba1\u6838\u548c\u968f\u540e\u7531\u6709\u8d44\u683c\u7684\u4eba\u5bf9\u836f\u54c1\u751f\u4ea7\u6279\u6b21\u7684\u8ba4\u8bc1\u662f\u5728\u5c06\u4ea7\u54c1\u8fdb\u53e3\u5230\u8be5\u5730\u533a\u7528\u4e8e\u4e34\u5e8a\u6216\u5546\u4e1a\u76ee\u7684\u4e4b\u524d\u7684\u8981\u6c42\u3002 \u6b64\u6b21\u5ba1\u6838\u6210\u529f\u540e\uff0cInvex\u5df2\u4e0ePeptron\u7b7e\u8ba2\u4e86\u4e00\u4efd\u521d\u6b65\u91c7\u8d2d\u8ba2\u5355\uff0c\u4e3aIIH ELVOLVE\u8bd5\u9a8c\u63d0\u4f9bPresendin\u548c\u5b89\u6170\u5242\u7684\u4e34\u5e8a\u6279\u6b21\u3002Invex\u7684\u4ed3\u50a8\u548c\u5206\u9500\u5408\u4f5c\u4f19\u4f34\u9884\u8ba1\u5c06\u5728\u77ed\u671f\u5185\u53d1\u8d27\uff0c\u5e76\u5b8c\u6210\u5fc5\u8981\u7684\u6807\u7b7e\u8981\u6c42\uff0c\u4ee5\u4fbf\u5728\u8bca\u6240\u5f00\u4e1a\u540e\u7acb\u5373\u53d1\u8d27\u3002 \u8bd5\u9a8c\u8d44\u91d1\u5145\u8db3 \u622a\u81f3\u53bb\u5e7412\u6708\u5f53\u5b63\u672b\uff0cInvex\u7684\u73b0\u91d1\u548c\u73b0\u91d1\u7b49\u4ef7\u7269\u4e3a3,140\u4e07\u7f8e\u5143\u3002 \u672c\u5b63\u5ea6\u7684\u73b0\u91d1\u6d41\u51fa\u603b\u989d\u4e3a60\u4e07\u7f8e\u5143\uff0c\u5305\u62ec\u4e0epreendin\u548c\u5b89\u6170\u5242\u8d2d\u4e70\u76f8\u5173\u7684\u4ea7\u54c1\u5236\u9020\u548c\u8fd0\u8425\u6210\u672c\uff0c\u4ee5\u51c6\u5907IIH EVOLVE\u7b2c\u4e09\u9636\u6bb5\u8bd5\u9a8c\uff0c\u7814\u7a76\u548c\u5f00\u53d1\u652f\u51fa\u4ee5\u53ca\u7ba1\u7406\u548c\u4f01\u4e1a\u6210\u672c\u3002 \u8be5\u516c\u53f8\u8868\u793a\uff0c\u5df2\u4ece\u5f53\u524d\u73b0\u91d1\u50a8\u5907\u4e2d\u83b7\u5f97\u8db3\u591f\u8d44\u91d1\u6765\u5b8c\u6210IIH\u6f14\u8fdb\u7b2c\u4e09\u9636\u6bb5\u7684\u8bd5\u9a8c\u3002<\/p>\n","protected":false},"author":5,"featured_media":18658,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"\n
Invex Therapeutics\u5728IIH\u8fdb\u5316\u9636\u6bb5\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u524d\u53d6\u5f97\u8fdb\u5c55<\/title>\n<meta name=\"description\" content=\"\u65e5\u524d\uff0cInvex Therapeutics (ASX: IXC)\u5728\u5176IIH EVOLVE 3\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u51c6\u5907\u5de5\u4f5c\u4e0a\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u5b9e\u73b0\u836f\u7269Presendin\u7528\u4e8e\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684\u5168\u7403\u6ce8\u518c\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics\u5728IIH\u8fdb\u5316\u9636\u6bb5\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u524d\u53d6\u5f97\u8fdb\u5c55\" \/>\n<meta property=\"og:description\" content=\"\u65e5\u524d\uff0cInvex Therapeutics (ASX: IXC)\u5728\u5176IIH EVOLVE 3\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u51c6\u5907\u5de5\u4f5c\u4e0a\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u5b9e\u73b0\u836f\u7269Presendin\u7528\u4e8e\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684\u5168\u7403\u6ce8\u518c\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-24T04:56:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T18:01:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-Presendin-2021-2022-manufacturing-tax-rebate-research-development-IIH-EVOLVE-clinical-trial.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Small Caps\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Small Caps\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/\",\"name\":\"Invex Therapeutics\u5728IIH\u8fdb\u5316\u9636\u6bb5\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u524d\u53d6\u5f97\u8fdb\u5c55\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-01-24T04:56:57+00:00\",\"dateModified\":\"2023-08-29T18:01:39+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\"},\"description\":\"\u65e5\u524d\uff0cInvex Therapeutics (ASX: IXC)\u5728\u5176IIH EVOLVE 3\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u51c6\u5907\u5de5\u4f5c\u4e0a\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u5b9e\u73b0\u836f\u7269Presendin\u7528\u4e8e\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684\u5168\u7403\u6ce8\u518c\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics\u5728IIH\u8fdb\u5316\u9636\u6bb5\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u524d\u53d6\u5f97\u8fdb\u5c55\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\",\"name\":\"Small Caps\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"caption\":\"Small Caps\"},\"description\":\"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=5\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics\u5728IIH\u8fdb\u5316\u9636\u6bb5\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u524d\u53d6\u5f97\u8fdb\u5c55","description":"\u65e5\u524d\uff0cInvex Therapeutics (ASX: IXC)\u5728\u5176IIH EVOLVE 3\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u51c6\u5907\u5de5\u4f5c\u4e0a\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u5b9e\u73b0\u836f\u7269Presendin\u7528\u4e8e\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684\u5168\u7403\u6ce8\u518c\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics\u5728IIH\u8fdb\u5316\u9636\u6bb5\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u524d\u53d6\u5f97\u8fdb\u5c55","og_description":"\u65e5\u524d\uff0cInvex Therapeutics (ASX: IXC)\u5728\u5176IIH EVOLVE 3\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u51c6\u5907\u5de5\u4f5c\u4e0a\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u5b9e\u73b0\u836f\u7269Presendin\u7528\u4e8e\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684\u5168\u7403\u6ce8\u518c\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/","og_site_name":"smallcapsCN","article_published_time":"2022-01-24T04:56:57+00:00","article_modified_time":"2023-08-29T18:01:39+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-Presendin-2021-2022-manufacturing-tax-rebate-research-development-IIH-EVOLVE-clinical-trial.jpg","type":"image\/jpeg"}],"author":"Small Caps","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Small Caps"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/","name":"Invex Therapeutics\u5728IIH\u8fdb\u5316\u9636\u6bb5\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u524d\u53d6\u5f97\u8fdb\u5c55","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-01-24T04:56:57+00:00","dateModified":"2023-08-29T18:01:39+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74"},"description":"\u65e5\u524d\uff0cInvex Therapeutics (ASX: IXC)\u5728\u5176IIH EVOLVE 3\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u51c6\u5907\u5de5\u4f5c\u4e0a\u53d6\u5f97\u4e86\u5f3a\u52b2\u8fdb\u5c55\uff0c\u8be5\u8bd5\u9a8c\u65e8\u5728\u5b9e\u73b0\u836f\u7269Presendin\u7528\u4e8e\u6cbb\u7597\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b(IIH)\u7684\u5168\u7403\u6ce8\u518c\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-makes-progress-ahead-iih-evolve-phase-three-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics\u5728IIH\u8fdb\u5316\u9636\u6bb5\u7b2c\u4e09\u671f\u4e34\u5e8a\u8bd5\u9a8c\u524d\u53d6\u5f97\u8fdb\u5c55"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74","name":"Small Caps","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","caption":"Small Caps"},"description":"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.","url":"https:\/\/smallcapscn.x5view.co\/?author=5"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4531"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4531"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4531\/revisions"}],"predecessor-version":[{"id":14410,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/4531\/revisions\/14410"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/18658"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}